Below is an extract from a text explaining the focus of the Longitude Prize (a £10 million reward offered for finding the solution to a major challenge of our time). Like many explanation texts, this one includes sub-headings intended to assist the reader.

Select the most appropriate sub-heading from each drop-down list.

The development of antibiotics has been vital to our survival, yet the rise of antimicrobial resistance is threatening to make them ineffective in the future.
The World Health Organization estimates that antibiotics treatments add an average of 20 years to all of our lives. But in the 80 years since the discovery of penicillin, our overuse of antibiotics has put pressure on bacteria to evolve resistance, leading to the emergence of untreatable superbugs that threaten the basis of modern medicine.
Clinicians often prescribe broad spectrum antibiotics to sick patients because doctors have to act quickly on imperfect information. These methods put selective pressure on microbes to evolve resistance to antibiotics.

Radical change is needed to address the global problem of growing anti-microbial resistance, to ensure a health care system that can sustainably control and treat infections.
We cannot outpace microbial evolution. A new broad-spectrum antibiotic, if applied with current methods, would eventually meet new forms of resistance. The overall solution involves a long-term path towards a more intelligent use of antibiotics enabling a future of more effective prevention, targeted treatments and smart clinical decision support systems.

The challenge for Longitude Prize will be set to create a cheap, accurate, rapid and easy-to-use point-of-care test kit for bacterial infections.

Point-of-care test kits will allow more targeted use of antibiotics, and an overall reduction in misdiagnosis and prescription. Effective and accurate point-of-care tests will form a vital part of the toolkit for stewardship of antibiotics in the future. This will ensure that the antibiotics we have now will be effective for longer and we can continue to control infections during routine and major procedures.